Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Top Cited Papers
- 3 May 2007
- journal article
- review article
- Published by Springer Nature in Nature Medicine
- Vol. 13 (5) , 552-559
- https://doi.org/10.1038/nm1589
Abstract
The identification of the antigen recognition receptors for innate immunity, most notably the Toll-like receptors, has sparked great interest in therapeutic manipulation of the innate immune system. Toll-like receptor agonists are being developed for the treatment of cancer, allergies and viral infections, and as adjuvants for potent new vaccines to prevent or treat cancer and infectious diseases. As recognition grows of the role of inappropriate Toll-like receptor stimulation in inflammation and autoimmunity, significant efforts have begun to develop antagonists to Toll-like receptors as well.Keywords
This publication has 93 references indexed in Scilit:
- HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cellsBlood, 2006
- Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cellsNature Cell Biology, 2006
- Toll-like receptors in systemic autoimmune diseaseNature Reviews Immunology, 2006
- On regulation of phagosome maturation and antigen presentationNature Immunology, 2006
- Pathogen Recognition and Innate ImmunityCell, 2006
- Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNANature Immunology, 2005
- The evolution of vertebrate Toll-like receptorsProceedings of the National Academy of Sciences, 2005
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004
- Toll-like receptor signallingNature Reviews Immunology, 2004
- TLR9 signals after translocating from the ER to CpG DNA in the lysosomeNature Immunology, 2004